M. Munchhof

发表

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

Tannishtha Reya, P. Beachy, Annelie Abrahamsson, 2009, Nature.

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

Tannishtha Reya, P. Beachy, Annelie Abrahamsson, 2009, Nature.

From partial to full agonism: identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor.

Michael D. Hamilton, S. Wright, A. Kalgutkar, 2013, Bioorganic & medicinal chemistry letters.

Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist response.

A. Kalgutkar, M. Munchhof, B. Lefker, 2011, Journal of medicinal chemistry.

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

M. Ammirati, A. Carlo, A. Mathiowetz, 2015, ACS medicinal chemistry letters.

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

J. O’Shea, A. Milici, B. Reitz, 2003, Science.

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Tim J. Wigle, T. Riera, R. Copeland, 2016, ACS medicinal chemistry letters.

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.

M. Munchhof, J. Litchfield, K. Karki, 2011, Bioorganic & medicinal chemistry letters.

The specificity of JAK3 kinase inhibitors.

M. Munchhof, T. Harris, P. Changelian, 2008, Blood.

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.

M. Munchhof, A. Shavnya, N. Patel, 2012, ACS medicinal chemistry letters.

Cross-Coupling Methods for the Large-Scale Preparation of an Imidazole−Thienopyridine: Synthesis of [2-(3-Methyl-3H-imidazol-4-yl)- thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine

Brian P. Jones, Ruth E. McDermott, M. Munchhof, 2003 .

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.

M. Munchhof, Jonathan L. Doty, Jianmin Sun, 2004, Bioorganic & medicinal chemistry letters.

An Asymmetric Route to Chiral, Nonracemic 2-Substituted Piperidines. Synthesis of (-)-Pipecoline, (+)-Coniine, and (-)-Coniceine

M. Munchhof, A. Meyers, 1995 .

A Novel Asymmetric Route to the 1,3‐Disubstituted Tetrahydroisoquinoline, (‐)‐Argemonine (XI).

M. Munchhof, A. Meyers, 1996 .

A Novel Asymmetric Route to the 1,3-Disubstituted Tetrahydroisoquinoline, (-)-Argemonine.

M. Munchhof, A. Meyers, 1996, The Journal of organic chemistry.

A NOVEL ROUTE TO CHIRAL, NONRACEMIC 1-ALKYL- AND 1-ARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES. SYNTHESIS OF (-)-SALSOLIDINE AND (+)-CRYPTOSTYLINE II

M. Munchhof, A. Meyers, 1995 .

Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119.

Bryan M. Li, David A. Price, A. Kalgutkar, 2013, Journal of medicinal chemistry.

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies

T. Riera, Katherine Cosmopoulos, K. Duncan, 2021, ACS medicinal chemistry letters.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Robert A Copeland, Nigel J Waters, Lei Jin, 2015, Nature chemical biology.

A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.

G. S. Walker, A. Kalgutkar, A. Mutlib, 2007, Chemical research in toxicology.

Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists.

F. Dicapua, M. Munchhof, Y. Abramov, 2008, Bioorganic & medicinal chemistry letters.

Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.

M. Munchhof, T. Harris, J. Driscoll, 2010, Bioorganic & medicinal chemistry letters.

The identification of orally bioavailable thrombopoietin agonists.

A. Marfat, M. Munchhof, T. Harris, 2009, Bioorganic & medicinal chemistry letters.

Pyrimidine benzamide-based thrombopoietin receptor agonists.

M. Munchhof, J. Driscoll, Jonathan L. Doty, 2007, Bioorganic & medicinal chemistry letters.

A Novel Asymmetric Route to Chiral, Nonracemic cis-2,6-Disubstituted Piperidines. Synthesis of (+)-Pinidinone and (+)-Monomorine

M. Munchhof, A. Meyers, 1995 .

Understanding the Impact of the P-loop Conformation on Kinase Selectivity

Cristiano R. W. Guimaraes, Brajesh K. Rai, Michael J. Munchhof, 2011, J. Chem. Inf. Model..

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Eliot Sugarman, Angel Guzman-Perez, G. S. Walker, 2011, ACS medicinal chemistry letters.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

Jodi Gureasko, W. Janzen, T. Riera, 2018, PloS one.

Chapter Twenty-Five - Case History: Xeljanz™ (Tofacitinib Citrate), a First-in-Class Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis

M. Munchhof, M. Flanagan, Matthew F Brown, 2014 .

GLI2 inhibition abrogates human leukemia stem cell dormancy

Richard A. Moore, T. Hudson, J. McPherson, 2015, Journal of Translational Medicine.

Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models

Zhou Zhu, R. Schwab, M. Munchhof, 2011 .

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

M. Hines, M. Munchhof, P. Changelian, 2010, Journal of medicinal chemistry.

Optimization of triazole -based TGR5 agonists towards orally available agents

Bryan M. Li, J. Warmus, D. Hepworth, 2013 .

Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.

Angel Guzman-Perez, Dawn Mather, W. Zavadoski, 2013, Bioorganic & medicinal chemistry.

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Robert A Copeland, Nigel J Waters, Lei Jin, 2016, ACS medicinal chemistry letters.

Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor.

A. Kalgutkar, K. Farley, M. Munchhof, 2011, Bioorganic & Medicinal Chemistry Letters.

Efficient Synthesis of 4-Amino-2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidin-5-ones: Practical Access to a Novel Chemotype in the Development of DGAT-1 Inhibitors

M. Munchhof, K. Karki, R. L. Dow, 2012, Synthesis.

Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor

R. Copeland, K. Duncan, N. Waters, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

GLI2 inhibition abrogates human leukemia stem cell dormancy

Richard A. Moore, T. Hudson, J. McPherson, 2015, Journal of Translational Medicine.

Intrinsic electrophilicity of a 4-substituted-5-cyano-6-(2-methylpyridin-3-yloxy)pyrimidine derivative: structural characterization of glutathione conjugates in vitro.

A. Kalgutkar, M. Munchhof, R. Robinson, 2011, Chemical research in toxicology.

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Lei Jin, R. Copeland, Elayne Penebre, 2014 .

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.

M. Munchhof, A. Shavnya, N. Patel, 2012, ACS medicinal chemistry letters.